- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Patent holdings for IPC class A61P 5/50
Total number of patents in this class: 623
10-year publication summary
|
27
|
32
|
27
|
37
|
45
|
44
|
43
|
34
|
35
|
12
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2961 |
15 |
| Sunshine Lake Pharma Co., Ltd. | 542 |
11 |
| Sirtris Pharmaceuticals, Inc. | 54 |
8 |
| Tsinghua University | 5426 |
7 |
| Novo Nordisk A/S | 2324 |
7 |
| Sanofi | 3836 |
7 |
| Boehringer Ingelheim Vetmedica GmbH | 1290 |
6 |
| Sanofi-Aventis Deutschland GmbH | 2738 |
6 |
| Janssen Pharmaceutica N.V. | 3839 |
6 |
| Boehringer Ingelheim International GmbH | 4629 |
5 |
| Beijing Protgen Ltd. | 21 |
5 |
| Cornell University | 3036 |
5 |
| Daiichi Sankyo Company, Limited | 1829 |
5 |
| Hua Medicine (Shanghai) Ltd. | 55 |
5 |
| Novartis AG | 11238 |
4 |
| AstraZeneca AB | 3042 |
4 |
| Amgen Inc. | 3779 |
4 |
| President and Fellows of Harvard College | 5792 |
4 |
| The George Institute for Global Health | 27 |
4 |
| Kyoto University | 2732 |
4 |
| Other owners | 501 |